Trospium Chloride Capsule, Extended Release
Product Images NDC 71205-917

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Trospium Chloride (NDC 71205-917). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

71205-917-30 (Trospium Er Jpg)

Label for Trospium Chloride 60 mg extended-release capsules, once-daily oral dosage form. Packaged by Proficient Rx LP, this prescription medication is supplied in capsules with a white opaque body and orange opaque cap, printed with "027" and "G60". Manufactured by Granules Pharmaceuticals Inc., the label includes storage instructions and medication safety warnings.*

FDA Label Image

Trosoiumstructure-jpg (Trospium Stucture Jpg)

Chemical structure diagram of the active ingredient Trospium Chloride, showing a bicyclic amine connected to a quaternary ammonium ion with a chloride counter ion and ester-linked moieties including hydroxyl and phenyl groups.*

FDA Label Image

Trospiumgraph1-jpg (Trospiumgraph1 Jpg)

A line graph showing plasma concentration (mg/mL) over time (hours post-dose) for Trospium chloride extended-release capsules 60 mg. The graph depicts the concentration rising to a peak around 4-6 hours after dosing and then gradually declining up to 24 hours, with error bars displayed at each time point.*

FDA Label Image

Trospiumgraph2-jpg (Trospiumgraph2 Jpg)

A line graph comparing the average change with standard error over 0, 1, 4, and 12 weeks of treatment for placebo versus 60 mg TROSPIUM CHLORIDE extended-release capsules. The graph shows data points with error bars and indicates statistical significance levels at weeks 1, 4, and 12.*

FDA Label Image

Trospiumgraph3-jpg (Trospiumgraph3 Jpg)

A line graph comparing the average percentage change over weeks of treatment between placebo and trospium chloride extended-release capsules. The x-axis represents weeks of treatment (0, 1, 4, 12), and the y-axis shows average percentage change. Two lines indicate data for placebo (N=300) and trospium chloride extended-release capsules (N=292), with statistical significance values noted at various time points.*

FDA Label Image

Trospiumgraph4-jpg (Trospiumgraph4 Jpg)

Line graph showing the average change with standard error over weeks of treatment comparing placebo and Trospium chloride extended-release capsules in a clinical study with 267 subjects in each group. The x-axis represents weeks of treatment (0, 1, 4, and 12), and the y-axis shows average change values, with p-values noted at different time points for statistical comparison between groups.*

FDA Label Image

Trospiumgraph5-jpg (Trospiumgraph5 Jpg)

Line graph showing average change with standard error bars over 12 weeks of treatment comparing placebo (N=276) and Trosopium chloride extended-release capsules (N=267). The Y-axis represents average change from 0 to -20, and the X-axis represents weeks 0, 1, 4, and 12. At each time point, Trosopium chloride shows greater average change reduction than placebo, with p-values less than 0.001 indicating statistical significance.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.